Study S002200

DUTCH Weight Control in Atrial Fibrillation Study, a Multi-center, Double-blind, Randomized, Parallel Group, Placebo-controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06184633
Acronym: DUTCH-WAIST
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 280
Start: 2024-07-21
Primary completion: 2027-04-10
Lead sponsor: Rijnstate Hospital
Conditions: Atrial Fibrillation; Obesity; Weight Loss
Interventions: DRUG:Semaglutide 3.2 MG/ML; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

The primary efficacy clinical endpoint of the trial is assessed at 12 months by a 7 point scale. Only the worst clinical outcome will be retained as the primary efficacy outcome [At 1 year follow-up]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.